Compare CSPI & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSPI | DTIL |
|---|---|---|
| Founded | 1968 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.4M | 97.7M |
| IPO Year | 1987 | 2019 |
| Metric | CSPI | DTIL |
|---|---|---|
| Price | $10.33 | $3.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 19.8K | ★ 200.6K |
| Earning Date | 02-09-2026 | 03-25-2026 |
| Dividend Yield | ★ 1.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $58,730,000.00 | $698,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $34.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $9.65 | $3.53 |
| 52 Week High | $21.95 | $8.82 |
| Indicator | CSPI | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 39.21 | 34.15 |
| Support Level | $10.30 | $3.53 |
| Resistance Level | $11.85 | $4.10 |
| Average True Range (ATR) | 0.77 | 0.25 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 18.17 | 7.41 |
CSP Inc develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems. The firm operates in two segments, namely Technology Solutions, where the company focuses on value-added reseller integrated solutions, including third-party hardware, software, and technical computer-related consulting, and High-Performance Products segments, where the company designs, manufactures, and delivers products and services to customers that require specialized cybersecurity services, networking, and signal processing. It generates a majority of its revenue from the Technology Solutions segment. Geographically, the company generates the majority of its revenue from the Americas.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.